Skip to content

Application of radiomics in precision diagnosis and treatment of pancreatic ductal adenocarcinoma

Application of radiomics in precision diagnosis and treatment of pancreatic ductal adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037064
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma

Interventions

Gold Standard:Pathologic diagnosis
Index test:A&#32
combined&#32
model&#32
of&#32
prediction&#32
(lymph&#32
and&#32
metastasis),&#32
assessment&#32
for&#32

Sponsors

Department of Radiology, North Hospital of Huashan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic ductal adenocarcinoma confirmed by pathology; 2. Patients who underwent thin slice CT scan within one month before operation; 3. Patients without history of radiotherapy, chemotherapy and immunotherapy; 4. The patient underwent radical resection of pancreatic cancer within one month.

Exclusion criteria

Exclusion criteria: 1. Patients who can not be identified in CT images due to artifacts or other reasons; 2. Patients whose CT images can not meet the requirements of thin slice scanning; 3. There are other primary malignant tumors in patients.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC, PPV, NPV;

Countries

China

Contacts

Public ContactJiawen,Zhang

Department of Radiology, North Hospital of Huashan Hospital Affiliated to Fudan University

zhangjw2000@126.com+86 13636465636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026